Detection of prostate cancer implies the presence of prostate specific antigen (PSA) in serum samples [73] and of annexin A3 (ANXA3) protein (<1 fg/mL) [74] as a noninvasive urine biomarker [75]. The gene discussed is ANXA3; the disease is prostate carcinoma.